Biozeen approach to steering covid-19 vaccine manufacturing dynamics

Vibin Joseph
3rd Nov, 2020
On a positive note, we have about 100+ vaccine candidates in trials across several platforms (Callaway, 2020).
On a positive note, we have about 100+ vaccine candidates in trials across several platforms (Callaway, 2020).

Compressed timeframes to clinical trials by executing steps in parallel, rather than a linear process (Thanh Le et al., 2020; Krammer, 2020).
Compressed timeframes to clinical trials by executing steps in parallel, rather than a linear process (Thanh Le et al., 2020; Krammer, 2020).

Similarly, to be up to speed, Biozeen is also enabling efficient production through analysis.

On a positive note, we have about 100+ vaccine candidates in trials across several platforms (Callaway, 2020).
Tailoring for COVID vaccine dynamics

With different formulation, specific upstream production and downstream requirements we leveraged our expertise in:

- Live attenuated vaccines: Yellow fever, MMR, Chicken pox
- Inactivated vaccine: Rabies, polio, Hepatitis A
- Recombinant/subunit vaccines: HPV, Hepatitis B, Shingles
- mABs
- Cell line: CHO, VERO, Sf9 insect cells
Tailoring for COVID vaccine dynamics

With different formulation, specific upstream production and downstream requirements we leveraged our expertise in:

- Live attenuated vaccines: Yellow fever, MMR, Chicken pox
- Inactivated vaccine: Rabies, polio, Hepatitis A
- Recombinant/subunit vaccines: HPV, Hepatitis B, Shingles
- mABs
- Cell line: CHO, VERO, Sf9 insect cells

And generalized these manufacturing approaches for a quick switch adaptable universal design of hardware and software through:

- Flexibility: Leveraging your existing resources into the entire production gambit
- Speed: Jump starting fast – Need of the hour!
- Cost: As you are accelerating the process in parallel, without waiting for confirmation of success in the previous step and elevating financial risk
- Humanized modular construction: On a need basis, customized to your facility for a rapid switch on
Tailoring for COVID vaccine dynamics

With different formulation, specific upstream production and downstream requirements we leveraged our expertise in:

- Live attenuated vaccines: Yellow fever, MMR, Chicken pox
- Inactivated vaccine: Rabies, polio, Hepatitis A
- Recombinant/subunit vaccines: HPV, Hepatitis B, Shingles
- mABs
- Cell line: CHO, VERO, Sf9 insect cells

And generalized these manufacturing approaches for a quick switch adaptable universal design of hardware and software through:

- Flexibility: Leveraging your existing resources into the entire production gambit
- Speed: Jump starting fast – Need of the hour!
- Cost: As you are accelerating the process in parallel, without waiting for confirmation of success in the previous step and elevating financial risk
- Humanized modular construction: On a need basis, customized to your facility for a rapid switch on

Ensuring high titers and yields in pilot scale production and supporting scalability for further clinical development
Key Result Parameters and Trend of Achievements

- 5 COVID vaccine manufacturers in 4 countries & 3 continents
- 24/7, 365 days
- New facility
- Empowered 900+ professionals to serve the industry
- Delivered solutions that are 65% energy efficient
- Rendering services to 20 countries in Americas, Asia, Africa, Europe and Oceania
- Served 48 customer across borders
- DSIR certified GMP compliant Bio pilot Laboratory for Microbiological & Physiological Testing

We are into the business of Saving Lives™